Suppr超能文献

低分子量肝素预防断指再植术中微血管阻塞

Low molecular weight heparin for prevention of microvascular occlusion in digital replantation.

作者信息

Lin Pei-Tzu, Wang Shu-Hui, Chi Ching-Chi

机构信息

Chang Gung Memorial Hospital, Chiayi, Department of Pharmacy, 6, Sec West, Chia-Pu Rd, Puzih, Chiayi, Taiwan, 61363.

Chang Gung University of Science and Technology, Department of Nursing, 2, Sec West, Chia-Pu Rd, Puzih, Chiayi, Taiwan, 61363.

出版信息

Cochrane Database Syst Rev. 2020 Apr 17;4(4):CD009894. doi: 10.1002/14651858.CD009894.pub3.

Abstract

BACKGROUND

The success of digital replantation is highly dependent on the patency of the repaired vessels after microvascular anastomosis. Antithrombotic agents are frequently used for preventing vascular occlusion. Low molecular weight heparin (LMWH) has been reported to be as effective as unfractionated heparin (UFH) in peripheral vascular surgery, but with fewer adverse effects. Its benefit in microvascular surgery such as digital replantation is unclear. This is an update of the review first published in 2013.

OBJECTIVES

To assess if treatment with subcutaneous LMWH improves the salvage rate of the digits in patients with digital replantation after traumatic amputation.

SEARCH METHODS

The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, AMED and CINAHL databases, and the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers, to 17 March 2020. The authors searched PubMed, China National Knowledge Infrastructure (CNKI) and Chinese Electronic Periodical Services (CEPS) on 17 March 2020 and sought additional trials from reference lists of relevant publications.

SELECTION CRITERIA

We included randomised or quasi-randomised controlled trials comparing treatment with LMWH versus any other treatment in participants who received digital replantation following traumatic digital amputation.

DATA COLLECTION AND ANALYSIS

Two review authors (PL, CC) independently extracted data and assessed the risk of bias of the included trials using Cochrane's 'Risk of bias' tool. Disagreements were resolved by discussion. We assessed the certainty of evidence using the GRADE approach.

MAIN RESULTS

We included two new randomised trials in this update, bringing the total number of included trials to four. They included a total of 258 participants, with at least 273 digits, from hospitals in China. Three studies compared LMWH versus UFH, and one compared LMWH versus no LMWH. The mean age of participants ranged from 24.5 to 37.6 years. In the studies reporting the sex of participants, there were a total of 145 men and 59 women. The certainty of the evidence was downgraded to low or very low because all studies were at high risk of performance or reporting bias (or both) and there was imprecision in the results due to the small numbers of participants. The three studies comparing LMWH versus UFH reported the success rate of replantation using different units of analysis (participant or digit), so we were unable to combine data from all three studies (one study reported results for both participants and digits). No evidence of a benefit in success of replantation was seen in the LMWH group when compared with UFH, regardless of whether the outcomes were reported by number of participants (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.87 to 1.10; 130 participants, 2 studies; very low-certainty evidence); or by number of digits (RR 0.97, 95% CI 0.90 to 1.04; 200 digits, 2 studies; low-certainty evidence). No studies reported the incidence of compromised microcirculation requiring surgical or non-surgical therapy, or any systemic/other causes of microvascular insufficiency. There was no evidence of a clear difference between the LMWH and UFH groups in occurrence of arterial occlusion (RR 1.08, 95% CI 0.16 to 7.10; 54 participants, 1 study; very low-certainty evidence) or venous occlusion (RR 0.81, 95% CI 0.20 to 3.27; 54 participants, 1 study; very low-certainty evidence). Two studies reported adverse effects. The LMWH and UFH groups showed no evidence of a difference in wound bleeding (RR 0.53, 95% CI 0.23 to 1.23; 130 participants, 2 studies; low-certainty evidence), haematuria (RR 0.43, 95% CI 0.09 to 2.11; 130 participants, 2 studies; very low-certainty evidence), ecchymoses (RR 0.82, 95% CI 0.21 to 3.19; 130 participants, 2 studies; very low-certainty evidence), epistaxis (RR 0.27, 95% CI 0.03 to 2.32; 130 participants, 2 studies; very low-certainty evidence), gingival bleeding (RR 0.18, 95% CI 0.02 to 1.43; 130 participants, 2 studies; very low-certainty evidence), and faecal occult blood (RR 0.27, 95% CI 0.03 to 2.31; 130 participants, 2 studies; very low-certainty evidence). We could not pool data on coagulation abnormalities as varying definitions and tests were used in the three studies. One study compared LMWH versus no LMWH. The success rate of replantation, when analysed by digits, was reported as 91.2% success in the LMWH group and 82.1% in the control group (RR 1.11, 95% CI 0.93 to 1.33; 73 digits, 1 study; very low-certainty evidence). Compromised microcirculation requiring surgical re-exploration, analysed by digits, was 11.8% in the LMWH group and 17.9% in the control group (RR 0.86, 95% CI 0.21 to 3.58; 73 digits, 1 study; very low-certainty evidence). Compromised microcirculation requiring incision occurred in five out of 34 digits (14.7%) in the LMWH group and eight out of 39 digits (20.5%) in the control group (RR 0.72, 95% CI 0.26 to 1.98; 73 digits; very low-certainty evidence). Microvascular insufficiency due to arterial occlusion, analysed by digits, was 11.8% in the LMWH group and 17.9% in the control group (RR 0.66, 95% CI 0.21 to 2.05; 73 digits, 1 study; very low-certainty evidence), and venous occlusion was 14.7% in the LMWH group and 20.5% in the control (RR 0.72, 95% CI 0.26 to 1.98; 73 digits, 1 study; very low-certainty evidence). The study did not report complications or adverse effects.

AUTHORS' CONCLUSIONS: There is currently low to very low-certainty evidence, based on four RCTs, suggesting no evidence of a benefit from LMWH when compared to UFH on the success rates of replantation or affect microvascular insufficiency due to vessel occlusion (analysed by digit or participant). LMWH had similar success rates of replantation; and the incidence rate of venous and arterial microvascular insufficiency showed no evidence of a difference between groups when LMWH was compared to no LMWH (analysed by digit). Similar rates of complications and adverse effects were seen between UFH and LMWH. There was insufficient evidence to draw conclusions on any effect on coagulation when comparing LMWH to UFH or no LMWH. The certainty of the evidence was downgraded due to performance and reporting bias, as well as imprecision in the results. Further adequately powered studies are warranted to provide high-certainty evidence.

摘要

背景

断指再植的成功高度依赖于微血管吻合术后修复血管的通畅情况。抗血栓药物常用于预防血管闭塞。据报道,低分子量肝素(LMWH)在外周血管手术中与普通肝素(UFH)效果相当,但不良反应较少。其在断指再植等微血管手术中的益处尚不清楚。这是对2013年首次发表的综述的更新。

目的

评估皮下注射低分子量肝素治疗能否提高创伤性截肢后断指再植患者手指的挽救率。

检索方法

Cochrane血管信息专家检索了Cochrane血管专业注册库、CENTRAL、MEDLINE、Embase、AMED和CINAHL数据库,以及世界卫生组织国际临床试验注册平台和ClinicalTrials.gov试验注册库,检索截至2020年3月17日的数据。作者于2020年3月17日检索了PubMed、中国知网(CNKI)和中国电子期刊服务(CEPS),并从相关出版物的参考文献列表中寻找其他试验。

入选标准

我们纳入了随机或半随机对照试验,比较低分子量肝素与其他任何治疗方法对创伤性断指后接受断指再植患者的治疗效果。

数据收集与分析

两位综述作者(PL、CC)独立提取数据,并使用Cochrane的“偏倚风险”工具评估纳入试验的偏倚风险。分歧通过讨论解决。我们使用GRADE方法评估证据的确定性。

主要结果

本次更新纳入了两项新的随机试验,使纳入试验总数达到四项。这些试验共纳入了来自中国医院的258名参与者,涉及至少273根手指。三项研究比较了低分子量肝素与普通肝素,一项研究比较了低分子量肝素与不使用低分子量肝素。参与者的平均年龄在24.5至37.6岁之间。在报告参与者性别的研究中,共有145名男性和59名女性。由于所有研究均存在较高的实施或报告偏倚风险(或两者皆有),且参与者数量较少导致结果存在不精确性,证据的确定性被降为低或极低。三项比较低分子量肝素与普通肝素的研究使用了不同的分析单位(参与者或手指)报告再植成功率,因此我们无法合并所有三项研究的数据(一项研究报告了参与者和手指的结果)。与普通肝素相比,低分子量肝素组在再植成功方面未见益处,无论结果是按参与者数量报告(风险比(RR)0.98,95%置信区间(CI)0.87至1.10;130名参与者,2项研究;极低确定性证据)还是按手指数量报告(RR 0.97,95%CI 0.90至1.04;200根手指,2项研究;低确定性证据)。没有研究报告需要手术或非手术治疗的微循环受损发生率,或任何系统性/其他微血管功能不全的原因。在动脉闭塞发生率(RR 1.08,95%CI 0.16至7.10;54名参与者,1项研究;极低确定性证据)或静脉闭塞发生率(RR 0.81,95%CI 0.20至3.27;54名参与者,1项研究;极低确定性证据)方面,低分子量肝素组与普通肝素组之间没有明显差异的证据。两项研究报告了不良反应。低分子量肝素组与普通肝素组在伤口出血(RR 0.53,95%CI 0.23至1.23;130名参与者,2项研究;低确定性证据)、血尿(RR 0.43,95%CI 0.09至2.11;130名参与者,2项研究;极低确定性证据)、瘀斑(RR 0.82,95%CI 0.21至3.19;130名参与者,2项研究;极低确定性证据)、鼻出血(RR 0.27,95%CI 0.03至2.32;130名参与者,2项研究;极低确定性证据)、牙龈出血(RR 0.18,95%CI 0.02至1.43;130名参与者,2项研究;极低确定性证据)和粪便潜血(RR 0.27,95%CI 0.03至2.31;130名参与者,2项研究;极低确定性证据)方面没有差异的证据。由于三项研究使用了不同的定义和检测方法,我们无法汇总凝血异常的数据。一项研究比较了低分子量肝素与不使用低分子量肝素组。按手指分析,低分子量肝素组的再植成功率报告为91.2%,对照组为82.1%(RR \1.11,95%CI 0.93至1.33;73根手指,1项研究;极低确定性证据)。按手指分析,需要手术再次探查的微循环受损情况在低分子量肝素组为11.8%,对照组为1 7.9%(RR 0.86,95%CI 0.21至3.58;73根手指,1项研究;极低确定性证据)。低分子量肝素组34根手指中有5根(14.7%)需要切开处理的微循环受损,对照组39根手指中有8根(20.5%)(RR 0.72,95%CI 0.26至1.98;73根手指;极低确定性证据)。按手指分析,因动脉闭塞导致的微血管功能不全在低分子量肝素组为11.8%,对照组为17.9%(RR 0.66,95%CI \0.21至2.05;73根手指,1项研究;极低确定性证据),静脉闭塞在低分子量肝素组为14.7%,对照组为20.5%(RR 0.72,95%CI 0.26至1.98;73根手指,1项研究;极低确定性证据)。该研究未报告并发症或不良反应。

作者结论

基于四项随机对照试验,目前证据的确定性为低或极低水平,并表明与普通肝素相比,低分子量肝素在再植成功率或因血管闭塞导致的微血管功能不全方面(按手指或参与者分析)未见益处。低分子量肝素的再植成功率相似;与不使用低分子量肝素组相比,低分子量肝素组在静脉和动脉微血管功能不全的发生率上没有差异(按手指分析)。普通肝素和低分子量肝素的并发症和不良反应发生率相似。在比较低分子量肝素与普通肝素或不使用低分子量肝素时,没有足够的证据得出关于对凝血的任何影响的结论。由于实施和报告偏倚以及结果的不精确性,证据的确定性被降低。需要进一步开展有足够样本量的研究以提供高确定性的证据。

相似文献

1
Low molecular weight heparin for prevention of microvascular occlusion in digital replantation.
Cochrane Database Syst Rev. 2020 Apr 17;4(4):CD009894. doi: 10.1002/14651858.CD009894.pub3.
2
Low molecular weight heparin for prevention of microvascular occlusion in digital replantation.
Cochrane Database Syst Rev. 2013 Jul 8(7):CD009894. doi: 10.1002/14651858.CD009894.pub2.
3
Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children.
Cochrane Database Syst Rev. 2020 Jun 18;6(6):CD005982. doi: 10.1002/14651858.CD005982.pub3.
5
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Cochrane Database Syst Rev. 2020 May 6;5(5):CD005259. doi: 10.1002/14651858.CD005259.pub4.
6
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Cochrane Database Syst Rev. 2020 Mar 13;3(3):CD012467. doi: 10.1002/14651858.CD012467.pub2.
7
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD012467. doi: 10.1002/14651858.CD012467.pub3.
8
Interventions for preventing thrombosis in solid organ transplant recipients.
Cochrane Database Syst Rev. 2021 Mar 15;3(3):CD011557. doi: 10.1002/14651858.CD011557.pub2.
9
Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.
Cochrane Database Syst Rev. 2021 Mar 29;3(3):CD001689. doi: 10.1002/14651858.CD001689.pub4.
10
Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.
Cochrane Database Syst Rev. 2017 Apr 21;4(4):CD007557. doi: 10.1002/14651858.CD007557.pub3.

引用本文的文献

1
Retrospective Analysis of Functional Outcome of Distal Fingertip Replants Without Heparin.
J Hand Surg Glob Online. 2024 May 3;7(2):272-276. doi: 10.1016/j.jhsg.2024.02.018. eCollection 2025 Mar.
5
Principles of microvascular surgery in the upper extremity.
Eur J Orthop Surg Traumatol. 2024 Oct;34(7):3647-3659. doi: 10.1007/s00590-023-03749-x. Epub 2023 Oct 24.
7
Complicated Replanted Finger, 34 Years after Revascularization.
Plast Reconstr Surg Glob Open. 2020 Nov 25;8(11):e3246. doi: 10.1097/GOX.0000000000003246. eCollection 2020 Nov.

本文引用的文献

1
3
Low molecular weight heparin for prevention of microvascular occlusion in digital replantation.
Cochrane Database Syst Rev. 2013 Jul 8(7):CD009894. doi: 10.1002/14651858.CD009894.pub2.
4
Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery.
Cochrane Database Syst Rev. 2011 Jun 15;2011(6):CD000536. doi: 10.1002/14651858.CD000536.pub2.
6
Anticoagulation following digital replantation.
J Hand Surg Am. 2011 Aug;36(8):1374-6. doi: 10.1016/j.jhsa.2011.03.019. Epub 2011 May 6.
7
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
J Clin Epidemiol. 2011 Apr;64(4):383-94. doi: 10.1016/j.jclinepi.2010.04.026. Epub 2010 Dec 31.
8
[Addition of antithrombosis in situ in the case of digital replantation: preliminary prospective study of 13 cases].
Chir Main. 2010 Oct;29(5):326-31. doi: 10.1016/j.main.2010.03.007. Epub 2010 Apr 27.
9
Safety of topical corticosteroids in pregnancy.
Cochrane Database Syst Rev. 2009 Jul 8(3):CD007346. doi: 10.1002/14651858.CD007346.pub2.
10
Clinical use of anticoagulants following replantation surgery.
J Hand Surg Am. 2008 Oct;33(8):1437-9. doi: 10.1016/j.jhsa.2008.08.009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验